ZEB2 overexpression plays a clear oncogenic role in early T-cell precursor leukemia (ETP-ALL) [28, 29]; therefore, direct application of T-bet or Zeb2 gain-of-function in CD8+ cells will likely be of little clinical utility. Here, ZEB2 is linked to acute lymphoblastic leukemia.